What changed
Repligen completed its acquisition of BioLife Solutions, with BioLife stockholders receiving $11.25 per share in cash and 0.1442 shares of Repligen common stock, plus cash in lieu of fractional shares. BioLife's biopreservation media portfolio, led by CryoStor, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. Repligen said it will provide additional detail on the transaction's expected impact on its 2026 financial outlook during its upcoming third quarter 2026 earnings call.
Why it matters
Repligen completed its acquisition of BioLife Solutions, with BioLife stockholders receiving $11.25 per share in cash and 0.1442 shares of Repligen common stock, plus cash in lieu of fractional shares